Wed, January 19, 2022
Tue, January 18, 2022
Mon, January 17, 2022
Fri, January 14, 2022
Thu, January 13, 2022
Wed, January 12, 2022
Tue, January 11, 2022
Mon, January 10, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy and Held Target at $122 on, Jan 13th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. buy-and-held-target-at-122-on-jan-13th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $122 on, Jan 13th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Tazeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021


These are the ratings of the 6 analyists that currently disagree with Tazeen


  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
  • Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $125 on, Thursday, December 9th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $145 on, Thursday, November 4th, 2021
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021

Publication Contributing Sources